OT-Scan Premier Biotech

OT-Scan Premier Biotech

Scanning and Reporting App

Free
Click to generate a QR code for easy access to the app on the App Store

About OT

  • Released
  • Updated
  • iOS Version
  • Age Rating
  • Size
  • Devices
  • Languages

Features

Developer of OT

OT-Scan Premier Biotech screenshot #1 for iPhone
OT-Scan Premier Biotech screenshot #2 for iPhone
OT-Scan Premier Biotech screenshot #3 for iPhone
OT-Scan Premier Biotech screenshot #4 for iPhone
OT-Scan Premier Biotech screenshot #5 for iPhone
OT-Scan Premier Biotech screenshot #6 for iPhone
🖼️Download
Icons↘︎
OT-Scan is the next innovation in drugs of abuse screening and reporting. Providing an easy to use, streamlined interface, the app captures and reports results within minutes. Take your testing program to the next level with OT-Scan. Designed to be used with OralTox®, Premier Biotech's patented lateral flow rapid oral fluid test. The OT-Scan app automates results reporting through an easy to use interface for the detection of relevant drugs of abuse including: AMP, BAR, BZO, COC, MET, MTD, OPI, OXY, PCP, THC and more. The OT-Scan app along with Premier Biotech’s software and technology offerings allows for seamless Integration capabilities with existing systems. This helps expedite the results reporting and data retrieval process that can save both time and money. Access to the app and data will be handled using username/password authentication on login. This allows validation within the app for a streamlined, secure workflow. Save Time And Reduce Errors Fast, accurate result capturing and reporting without the need for manual interpretation. A fully automated solution. Electronic Consent Donor and Collector consent is captured directly within the app, utilizing on screen signing technology. QR Code Capture Built in QR scanning functionality ties the specific test to the individual order, alleviating user input and potential human error. Secure Results Reporting Data is securely transmitted between the app and the defined data center and/or ATS software using web services. Role Based Permissions Access to the app and data is handled using user/pass authentication. This allows varied levels of access based on customer request. In App Tutorial And Support Step by step instructions outline both the collection and app process, with in-app options to support. Platform Integration The OT-Scan app integrates with existing ATS/Managed solutions for data retrieval and secure results reporting in real-time. *Not for diagnostic use Validated for iPhone 6S and newer.
Show less

What's New in OT

+1

2.6.2

December 6, 2024

Changed some configuration field for a smoother information upload and download

Reviews of OT

Upgrade

Great concept but it needs to be upgraded to work on with the cameras on iPhones above an 11

Alternatives to OT

FAQ

Is OT compatible with iPad devices?

No, OT doesn’t work on iPad devices.

Who is the app developer of OT?

The OT app was built by Premier Biotech, Inc..

What’s the minimum iOS version supported by the OT app?

The minimum supported iOS version for the app is 10.0.

What is the overall user rating for OT?

With a rating of 4.4 out of 5, OT is one of the top-rated apps in its category.

What’s the app category of OT?

The Main Genre Of The Ot App Is Medical.

What OT application version is the latest one?

2.6.2 is the most recent version of OT.

What is the latest update date for OT?

The last update for OT was on December 12, 2024.

Could you provide information on the release date of OT?

OT was first released on February 5, 2023.

What is the age rating of OT?

The OT app is suitable for Premier Biotech, Inc. years of age.

What are the languages supported by OT?

OT is available in .

Is OT accessible through Apple Arcade's subscription model?

Unfortunately, OT is not on Apple Arcade.

Does OT allow for in-app purchases?

No, OT does not allow for in-app purchases.

Can I use OT with Apple Vision Pro?

No, you cannot use OT with Apple Vision Pro.

Does OT display any ads?

No, OT does not display any ads.